TROPHIT1—a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients by B.C. Köhler, G.M. Haag, L. Le Cornet, P. Hoffmeister-Wittmann, M. Schmidt, A. Manjunath, N. Vaquero-Siguero, M. Jenzer, M. Gimmel, A. Stahler, A. Stein, M. Reichert, S. Kasper, M. Bitzer, D. Jäger, C. Springfeld, T.F. Weber, S. Fröhling, K. Steindorf, A. Trumpp, R.F. Schlenk, R. Jackstadt

Get full text